about
sameAs
TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesisCD47 agonist peptides induce programmed cell death in refractory chronic lymphocytic leukemia B cells via PLCγ1 activation: evidence from mice and humansChromosomal translocations and karyotype complexity in chronic lymphocytic leukemia: a systematic reappraisal of classic cytogenetic data.A new recurrent and specific cryptic translocation, t(5;14)(q35;q32), is associated with expression of the Hox11L2 gene in T acute lymphoblastic leukemia.Identical abnormality of the short arm of chromosome 18 in two Philadelphia-positive chronic myelocytic leukemia patients with erythroblastic transformation, resulting in duplication of BCR-ABL1 fusion.Concomitant heterochromatinisation and down-regulation of gene expression unveils epigenetic silencing of RELB in an aggressive subset of chronic lymphocytic leukemia in malesRefinement of 1p36 alterations not involving PRDM16 in myeloid and lymphoid malignanciest(5;14)/HOX11L2-positive T-cell acute lymphoblastic leukemia. A collaborative study of the Groupe Français de Cytogénétique Hématologique (GFCH).Acquired initiating mutations in early hematopoietic cells of CLL patients.Deregulation of cyclin D2 by juxtaposition with T-cell receptor alpha/delta locus in t(12;14)(p13;q11)-positive childhood T-cell acute lymphoblastic leukemia.Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerationsSpecific chromosomal IG translocations have different prognoses in chronic lymphocytic leukemia.Trisomy 4 associated with double minute chromosomes and MYC amplification in acute myeloblastic leukemia.NUP98 rearrangements in hematopoietic malignancies: a study of the Groupe Francophone de Cytogénétique Hématologique.Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström's macroglobulinemia.Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors.STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model.Haploinsufficiency for NR3C1, the gene encoding the glucocorticoid receptor, in blastic plasmacytoid dendritic cell neoplasms.Spliceosome and other novel mutations in chronic lymphocytic leukemia and myeloid malignancies.Chromosomal translocations involving the IGH@ locus in B-cell precursor acute lymphoblastic leukemia: 29 new cases and a review of the literature.Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC-13 lympho-C study.Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia.Recurrence of OTT-MAL fusion in t(1;22) of infant AML-M7.Chronic lymphocytic leukemia: Time to go past genomics?Cytogenetics in the management of hematologic malignancies: an update by the Groupe francophone de cytogénétique hématologique (GFCH).Cytogenetics in the management of chronic lymphocytic leukemia: an update by the Groupe francophone de cytogénétique hématologique (GFCH).A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection.Chronic lymphocytic leukaemia genomics and the precision medicine era.Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study.Functional assessment of p53 in chronic lymphocytic leukemia.EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia.Establishment and characterization of a new human erythroleukemic cell line, ERY-1.Evaluating abbreviated induction with fludarabine, cyclophosphamide, and dose-dense rituximab in elderly patients with chronic lymphocytic leukemia.Additional trisomies amongst patients with chronic lymphocytic leukemia carrying trisomy 12: the accompanying chromosome makes a difference.Prognosis of Binet stage A chronic lymphocytic leukemia patients: the strength of routine parameters.Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma.Hypoxia enhances human B19 erythrovirus gene expression in primary erythroid cells.Correction: Refinement of 1p36 Alterations Not Involving PRDM16 in Myeloid and Lymphoid Malignancies.IGHV gene mutational status and LPL/ADAM29 gene expression as clinical outcome predictors in CLL patients in remission following treatment with oral fludarabine plus cyclophosphamide.Cytogenetic study of 75 erythroleukemias.
P50
Q28507642-16AD9973-3085-4EB7-9C95-767F1A2CE68BQ28507642-42B4C7E2-52E9-4644-ADD9-065FD8D1B9C3Q28543785-FDCC5AE6-C930-42BF-A3C4-013343E92F3DQ30685440-A8ACB66F-1A17-4151-9884-C430942BBFE9Q33182502-56DA19A1-276F-43FB-9451-4FA29AEF8845Q33185115-1524FA67-640D-4724-B5F6-30AE45DDE5E1Q33742884-4F400CF4-4F65-4D10-84E7-9D2371009C10Q34062347-9437B916-93EB-444F-B10D-DB8F11FADC1AQ34230063-236EFB7C-20C7-4050-A0AE-D6053D19ED9CQ34424293-1F97BBED-5D27-4B80-8A43-2DE49801E567Q34503575-14DB5CFC-5C20-4825-AFB9-94156AF75E74Q35029461-4BD7788B-959A-4845-A2C3-825063884794Q35824945-17CA3E85-00F0-4BAE-99ED-30C3AD6DD632Q35974584-45408A0E-1D1A-4D81-98DC-8DFE1F4BB339Q36391820-C1E5E3A7-D974-41B3-B52C-D869659AEC4FQ36862542-A4428579-A994-4B04-B018-E9CDE2E2F969Q37140491-88961FF7-FC8B-4B8F-B5C9-20E9D6FC6A91Q37273194-CE7E6FF9-27BE-4C42-9198-0300C613522CQ37299013-93A3C036-EFFD-4F4F-A944-20E6BE51611BQ38000919-A000D123-99C6-4747-B2FF-00E5E8E18614Q38119337-6D4A896B-D96E-46A4-AEC7-E6D2B1642E47Q38270640-DBFBDCD6-9507-4366-B71B-47C3ACC1C92FQ38447382-B1BA5A92-60B2-4CB4-A769-F891823D59DFQ38491079-A8F7511D-7AD5-46AF-BEF8-A3F1C44F108AQ38708220-4A3ED7E7-BD8D-44FF-BD4A-C1F9C85E2CA4Q38910566-91991DB4-AD6D-4147-BD78-B9C5FB22E888Q38954362-6405FD2E-A599-40F8-ADC0-796D86391A26Q39010730-0C92C08E-DA42-4F26-A584-8E2DA65EC809Q39263974-99FE1F4A-AA63-4C86-B348-6C73909A9425Q39876261-3F7A9109-BE24-4AAD-8473-9ADB38435CA5Q40298340-06F54AA9-E2A6-485D-9B86-B6EBC84F00C7Q40455172-BEE615A6-B524-420A-81EB-A403C4ED0CF0Q40505919-444DA98A-D0EF-4503-866F-DE33E8D9FACDQ41125227-B5C95382-5071-4B7B-A182-009267B5E14EQ42399823-6705B34E-FD35-4AE7-B8B9-108A8CABEF11Q42925708-B773E2DA-CEF0-4EBD-8BD2-823A8782B6C2Q44734725-56C40A9B-C288-4EC8-964C-20D7D674FF22Q45029310-C5FFDD4D-2FDE-4DB3-A492-61C19D735F8CQ46034452-4756E57F-72FB-408E-A5B7-9AD39E8D4D05Q46064600-4DC7E264-8C22-42D1-9CCB-6EDA22E9D62D
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Florence Nguyen-Khac
@ast
Florence Nguyen-Khac
@en
Florence Nguyen-Khac
@es
Florence Nguyen-Khac
@sl
type
label
Florence Nguyen-Khac
@ast
Florence Nguyen-Khac
@en
Florence Nguyen-Khac
@es
Florence Nguyen-Khac
@sl
prefLabel
Florence Nguyen-Khac
@ast
Florence Nguyen-Khac
@en
Florence Nguyen-Khac
@es
Florence Nguyen-Khac
@sl
P106
P21
P31
P496
0000-0003-3107-6668